GenEmbryomics, a medical genetics company with world-leading intellectual property, today the appointment of a further independent director to its board. This strategic move is part of the company’s preparation for listing on a major US national exchange, underscoring its commitment to global expansion and enhancing corporate governance standards.
“We are thrilled to welcome San Diego-based Saadia Basharat to our Board of Directors at this pivotal time,” said Paul Viney, Chairman of GenEmbryomics. Her appointment further strengthens our board with directors who bring a wealth of experience and expertise in healthcare, biotechnology, and strategic business development. We are confident that her contribution will be invaluable as we continue to advance our mission and prepare for our next phase of growth.”
Nick Murphy, PhD, Founder and CEO of GenEmbryomics, said, “The inclusion of Saadia on our board is a further significant milestone for GenEmbryomics. Saadia’s deep understanding of the pharmaceutical and biotech industries, combined with her expertise in programme strategy and business development, will undoubtedly enhance our capabilities in navigating the complex landscape of medical genetics. She will play a critical role in guiding our strategic direction as we move towards our US national exchange listing.”
Saadia Basharat, principal at Alacrita’s US West Coast consulting business, has a decade of experience in tech transfer and consulting and has been pivotal in supporting biotech and pharma companies through critical growth junctures. Her expertise spans programme prioritisation, disease area and indication prioritisation, and partnering strategy. Saadia’s academic background includes an honours degree in biomedical informatics, a Master of Science degree in molecular medicine, and a PhD in neuroendocrinology from Imperial College.
The appointment of Basharat will further strengthen GenEmbryomics’ industry position, driving forward its strategic initiatives and enhancing its governance as the company continues on its journey towards a US national exchange listing.